Skip to Main Content

Author Details

Malcolm A Smith
National Cancer Institute
1991
253
67
PMIDPaper TitleJournal TitlePublished Year
36250964Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma.Pediatr Blood Cancer2023
36250964Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma.Pediatr Blood Cancer2023
37584517Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors.Cancer Res2023
37339930In vivo activity of the dual SYK/FLT3 inhibitor TAK-659 against pediatric acute lymphoblastic leukemia xenografts.Pediatr Blood Cancer2023
37140091In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.Pediatr Blood Cancer2023
37267580The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer.J Clin Oncol2023
37441939Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.Eur J Cancer2023
37115514Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.Neuro Oncol2023
37584517Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors.Cancer Res2023
37115514Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.Neuro Oncol2023
37441939Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.Eur J Cancer2023
37339930In vivo activity of the dual SYK/FLT3 inhibitor TAK-659 against pediatric acute lymphoblastic leukemia xenografts.Pediatr Blood Cancer2023
37140091In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.Pediatr Blood Cancer2023
37267580The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer.J Clin Oncol2023
34802040Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.Lab Invest2022
35657346Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.Mol Cancer Ther2022
35839426Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.J Clin Oncol2022
36381237Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.Cancer Res Commun2022
36050548The genomic landscape of pediatric acute lymphoblastic leukemia.Nat Genet2022
35467749Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.Neuro Oncol2022
34802040Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.Lab Invest2022
35312779Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma.Mol Cancer Ther2022
35307742Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.Neuro Oncol2022
34840026Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.Eur J Cancer2022
35839426Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.J Clin Oncol2022
35467749Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.Neuro Oncol2022
35657346Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.Mol Cancer Ther2022
36381237Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.Cancer Res Commun2022
36050548The genomic landscape of pediatric acute lymphoblastic leukemia.Nat Genet2022
35312779Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma.Mol Cancer Ther2022
35307742Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.Neuro Oncol2022
34840026Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.Eur J Cancer2022
33298592ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium.Mol Cancer Ther2021
33631016A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.Neuro Oncol2021
34108262International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer.Mol Cancer Ther2021
33619171The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.Clin Cancer Res2021
33504555Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.Clin Cancer Res2021
33601323Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.Eur J Cancer2021
33089597In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium.Pediatr Blood Cancer2021
33298592ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium.Mol Cancer Ther2021
34453478In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC).Pediatr Blood Cancer2021
34536944Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.Eur J Cancer2021
33601323Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.Eur J Cancer2021
33619171The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.Clin Cancer Res2021
33504555Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.Clin Cancer Res2021
33631016A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.Neuro Oncol2021
34453478In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC).Pediatr Blood Cancer2021
34536944Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.Eur J Cancer2021
34108262International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer.Mol Cancer Ther2021
33089597In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium.Pediatr Blood Cancer2021
  • 1 - 50 of 506

Recommended Authors

Juan C Vasquez
Yale School of Medicine
Career Start Year 2015
Number of shared co-authors 0
Thai Hoa Tran
Universite de Montreal
Career Start Year 2013
Number of shared co-authors 16
Bhuvana A Setty
Ohio State University College of Medicine/Nationwide Children's Hospital
Career Start Year 2011
Number of shared co-authors 8
Amulya A Nageswara Rao
Mayo Clinic
Career Start Year 2009
Number of shared co-authors 18
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Yana Pikman
Dana Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 6
Sabine Mueller
University Children's Hospital Zurich
Career Start Year 2005
Number of shared co-authors 38
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 6
Eugene I Hwang
Children's National Hospital. Electronic address: .
Career Start Year 2004
Number of shared co-authors 19
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 3
Christopher C Porter
Emory University School of Medicine
Career Start Year 2003
Number of shared co-authors 11
Nicholas G Gottardo
Perth Children's Hospital
Career Start Year 2002
Number of shared co-authors 29
Noah Federman
University of California los angeles
Career Start Year 2001
Number of shared co-authors 10
Shahrad Rod Rassekh
British Columbia Children's Hospital, The University of British Columbia
Career Start Year 1998
Number of shared co-authors 13
Scott C Borinstein
Vanderbilt University Medical Center
Career Start Year 1998
Number of shared co-authors 10
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 3
Rishi R Lulla
Hasbro Children's Hospital, Brown University.
Career Start Year 1997
Number of shared co-authors 28
Najat C Daw
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 26
Jaume Mora
Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu
Career Start Year 1996
Number of shared co-authors 52
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 12
Bill H Chang
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 11
Anne Bendel
Children's Hospitals and Clinics of Minnesota
Career Start Year 1993
Number of shared co-authors 35
Maura Massimino
Fondazione IRCCS Istituto Nazionale dei Tumori
Career Start Year 1990
Number of shared co-authors 35
Murali Chintagumpala
Texas Children's Cancer Center, Baylor College of Medicine
Career Start Year 1990
Number of shared co-authors 48
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 14
Laurence Brugi??res
Universite Paris-Saclay
Career Start Year 1988
Number of shared co-authors 29
David M Loeb
Children's Hospital at Montefiore.
Career Start Year 1986
Number of shared co-authors 16
Alan S Wayne
Cancer and Blood Disease Institute, Children's Hospital Los Angeles
Career Start Year 1986
Number of shared co-authors 13
Eric Bouffet
The Hospital for Sick Children
Career Start Year 1981
Number of shared co-authors 67
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 2

Collaborators

Peter J Houghton
The University of Texas Health Science Center at San Antonio
Co-authored papers 110
John M Maris
Children's Hospital of Philadelphia
Co-authored papers 83
Edward A Kolb
Co-authored papers 80
Richard Gorlick
University of Texas MD Anderson Cancer Center
Co-authored papers 79
Richard B Lock
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Co-authored papers 78
Charles Patrick Reynolds
Cancer Center, Texas Tech University Health Sciences Center
Co-authored papers 74
Stephen T Keir
Co-authored papers 63
Raushan T Kurmasheva
The University of Texas Health Science Center at San Antonio
Co-authored papers 53
Christopher L Morton
St. Jude Children's Research Hospital.
Co-authored papers 49
Daniela S Gerhard
National Cancer Institute
Co-authored papers 23
Gregory H Reaman
National Cancer Institute
Co-authored papers 23
Jaime M Guidry Auvil
National Cancer Institute
Co-authored papers 21
Charles G Mullighan
St Jude Children's Research Hospital
Co-authored papers 20
Stephen P Hunger
Children's Hospital of Philadelphia
Co-authored papers 17
Kathryn Evans
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Co-authored papers 17
Jinghui Zhang
Changhai Hospital, Second Military Medical University
Co-authored papers 16
Meenakshi Devidas
St Jude Children's Research Hospital
Co-authored papers 13
Marco A Marra
University of British Columbia
Co-authored papers 11
Richard A Moore
Co-authored papers 11
Mignon L Loh
University of Washington
Co-authored papers 10
Javed Khan
Center for Cancer Research, National Cancer Institute
Co-authored papers 10
Julie M Gastier-Foster
Baylor College of Medicine
Co-authored papers 10
Gilles Vassal
Co-authored papers 10
Soheil Meshinchi
Fred Hutchinson Cancer Research Centre
Co-authored papers 9
Andrew J Mungall
Co-authored papers 9
Yussanne Ma
Co-authored papers 9
Wendong Zhang
University of Texas MD Anderson Cancer Center
Co-authored papers 8
Tanja M Davidsen
Co-authored papers 8
Leandro C Hermida
University of Pittsburgh
Co-authored papers 8
Richard Simon
National Cancer Institute
Co-authored papers 8
Release 1.2